Ophthalmic Disorders Resource Center

Click on the subcategory below to find drug monographs for that particular area.

USPSTF Revisits Eye Screening for Seniors

The USPSTF has concluded that there is currently insufficient evidence to assess the benefits and harms of screening for impaired visual acuity in older adults.

Smart' intelli-Case Cleared by FDA

The FDA has cleared the intelli-Case for use with hydrogen peroxide solutions.

Eye Bacteria Changes With Contact Lenses

Changes in bacteria populations may be one reason why people who wear contact lenses are more prone to eye infections, a new study suggests.

Ophthalmic NSAIDs for Common Indications Compared

A recent review compared published data on the efficacy of several ophthalmic nonsteroidal anti-inflammatory drugs (NSAIDs), within and outside their FDA-approved uses.

Seizure Drug Boosts MS Patient Eyesight

New research suggests that a medication indicated to treat seizures could also reduce the risk of nerve damage and blindness in patients with multiple sclerosis (MS).

Ocular Syphilis: What Clinicians Should Know

The Centers for Disease Control and Prevention (CDC) has issued a clinical advisory on ocular syphilis due to recent confirmed and suspected cases in several states.

Eye Complications Possible with Measles

In the midst of the current resurgence of measles across the United States, ophthalmologists are warning that even before the telltale skin rash appears, the infection typically shows up in the eyes.

FDA Expands Eylea Indication

The Food and Drug Administration (FDA) has granted expanded the use of Eylea (aflibercept; Regeneron) injection to treat diabetic retinopathy in patients with diabetic macular edema (DME).

News

Dry Eyes: Updates on Risk Factors, Diagnosis, Tx

As dry eyes is one of the most common reasons for patient visits to eye care professionals, the latest issue of the journal Optometry and Vision Science focuses on progress in the risk factors, diagnosis, and treatment of dry eye disease.

BromSite NDA Accepted for Post-Cataract Surgery

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for BromSite (0.075% bromfenac; InSite Vision) for the treatment of inflammation and prevention of ocular pain post-cataract surgery.

Particulate Matter Leads to Recall of Some Allergan Ophthalmic Products

Allergan plc. announced a voluntary recall of specific lots of REFRESH Lacri-Lube, REFRESH PM, FML (fluorometholone ophthalmic ointment) 0.1%, and Blephamide (sulfacetamide sodium and prednisolone acetate ophthalmic ointment USP) 10%/0.2% due to the presence of particular matter.

Clinical Charts

Make prescribing decisions with our charts and treatment algorithms.

Featured courses from mycme

Cannabinoid Offers Modest Relief From Pain, SpasticityExternal web site

Among the many issues clinicians face today, staying current with advances in medicine is becoming ...

CME|CE 0.25 Credits

Pulmonology, Pediatrics, Ophthalmology, and ENTExternal web site

This module reviews all topics on the NCCPA examination blueprint relating to Pulmonology, Ophthalmology, and ...

CME 4.50 Credits

Vitreomacular Traction, Macular Hole Treatment, and Injection TechniqueExternal web site

This webcast will discuss the pathophysiology and diagnostic criteria of VMA/VMT and treatment options for ...

CME 1.50 Credits

Sign Up for Free e-newsletters